JMP reiterates NPS at outperform

NPS Pharmaceuticals Inc. was reiterated at market outperform with a $22 target price by JMP Securities analysts Charles C. Duncan and Anthony Ostrea after the company announced the appointment of N. Anthony Coles as president a chief operating officer. They said Coles brings strong experience in the commercialization of new drugs and in management of a large pharmaceutical sales organization and will be valuable in the anticipated launch of Preos in the first half of 2006.Shares of the Salt Lake City-based biopharmaceutical company were up $0.09, or 0.90%, at $10.09 on volume of 463,409 shares versus the three-month running average of 528,074 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.